You are in: eMedicine Specialties > Emergency Medicine > EAR, NOSE, AND THROAT SinusitisArticle Last Updated: Aug 8, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Elicia S Kennedy, MD, Clinical Assistant Professor, Department of Emergency Medicine, University of Arkansas for Medical Sciences Elicia S Kennedy is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine Editors: Daniel J Dire, MD, FACEP, FAAP, FAAEM, Clinical Associate Professor, Department of Emergency Medicine, University of Texas-Houston; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Mark W Fourre, MD, Program Director, Department of Emergency Medicine, Maine Medical Center; Associate Clinical Professor, Department of Surgery, University of Vermont School of Medicine; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital Author and Editor Disclosure Synonyms and related keywords: sinusitis, sinus inflammation, sinus infection, paranasal sinuses, inflammation of paranasal sinuses, infection of paranasal sinuses, nasopharyngeal flora, sinus disease, upper respiratory infections, URI, acute sinusitis, subacute sinusitis, chronic sinusitis, bacterial sinusitis, allergic rhinitis, severe allergic rhinitis, rhinoviral infection, maxillary sinusitis, Haemophilus influenzae, H influenzae, Streptococcus pneumoniae, S pneumoniae, Bacteroides, Peptostreptococcus, Fusobacterium, Moraxella catarrhalis, M catarrhalis, Staphylococcus aureus, S aureus, Candida, Aspergillus, Phycomycetes INTRODUCTIONBackgroundSinusitis is the inflammation/infection of 1 or more paranasal sinuses and occurs with obstruction of the normal drainage mechanism. It is traditionally subdivided into acute (symptoms lasting <3 wk), subacute (symptoms lasting 3 wk to 3 mo), and chronic (symptoms lasting > 3 mo). PathophysiologyThe paranasal sinuses, a part of the upper respiratory tract, are in direct communication with the nasopharynx. The sinuses are normally sterile. Because of the proximity to nasopharyngeal flora, obstruction can cause bacterial infection. Diseases that obstruct drainage can result in a reduced ability of the paranasal sinuses to function normally. The sinus ostia may become occluded, leading to mucosal congestion. The mucociliary transport system becomes impaired, leading to more stagnation of secretion and epithelial damage, followed by decreased oxygen tension and subsequent bacterial growth. FrequencyUnited StatesAn estimated more than 30 million patients in the United States have sinus disease. Upper respiratory infections (URIs) are one of the most common presentations in the ED. A viral infection associated with the common cold is the most frequent etiology of acute sinusitis. Only a small percentage (as low as 2%) of viral sinusitis cases are complicated by bacterial sinusitis. The challenge is to differentiate a simple URI and allergic rhinitis from sinusitis. Medical treatment is expensive, with an estimated $5 billion spent annually; another $60 billion is spent on surgical treatment each year. Mortality/MorbiditySinusitis is rarely life threatening, but the close proximity of the paranasal sinuses to the central nervous system, the multiple fascial plains of the neck, and the associated venous and lymphatic channels can lead to serious complications. AgeAn estimated 5-10% of URIs in children are related to sinusitis, while up to 10% of URIs in adults are related to sinusitis. Sinusitis is rare in children younger than 1 year because the sinuses are poorly developed before that age. CLINICALHistory
Physical
CausesAcute sinusitis is usually bacterial in origin. A URI or severe allergic rhinitis leading to obstruction of the ostia and stasis of drainage often precedes it.
DIFFERENTIALSHeadache, Cluster Headache, Migraine Headache, Tension Otitis Media
|
| Drug Name | Oxymetazoline (Afrin) |
|---|---|
| Description | Applied directly to mucous membranes, where it stimulates alpha-adrenergic receptors and causes vasoconstriction. Decongestion occurs without drastic changes in blood pressure, vascular redistribution, or cardiac stimulation. |
| Adult Dose | 2-3 sprays or 2-3 gtt of 0.05% solution in each nostril bid Use for maximum of 3 d only; patients can become dependent |
| Pediatric Dose | <6 years: 2-3 gtt of 0.025% solution in each nostril bid >6 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; MAOI therapy |
| Interactions | Hypotensive action of guanethidine may be reversed; concurrent administration with methyldopa may result in an increased vasopressor response; concurrent use of MAOIs and ephedrine may result in hypertensive crisis; pressor sensitivity to mixed-acting agents such as ephedrine may be increased; guanethidine potentiates effects of epinephrine and inhibits effects of ephedrine; phenothiazines may reverse action of nasal decongestants such as oxymetazoline; TCAs potentiate vasopressor response and may result in dysrhythmias |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in hyperthyroidism, coronary artery and ischemic heart disease, diabetes mellitus, increased intraocular pressure, or prostatic hypertrophy; because of increase in vasoconstriction, patients with hypertension may experience change in blood pressure; do not use topical decongestants for longer than 3-5 d |
| Drug Name | Phenylephrine (Neo-Synephrine) |
|---|---|
| Description | A strong postsynaptic alpha-receptor stimulant with little effect on the beta-receptors of the heart. |
| Adult Dose | 1-2 sprays per nostril q3-4h |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; severe hypertension; ventricular tachycardia |
| Interactions | Bretylium may potentiate action of vasopressors on adrenergic receptors, possibly resulting in arrhythmias; MAOIs may significantly enhance adrenergic effects of phenylephrine, and pressor response may be increased 2- to 3-fold; guanethidine may increase pressor response of direct-acting vasopressors, possibly resulting in severe hypertension |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in elderly patients, hyperthyroidism, myocardial disease, bradycardia, partial heart block, or severe arteriosclerosis; in hypovolemia, use is not a substitute for replacement of blood, fluids and electrolytes, and plasma (these should be restored promptly when loss has occurred) |
| Drug Name | Pseudoephedrine (Sudafed) |
|---|---|
| Description | Stimulates vasoconstriction by directly activating the alpha-adrenergic receptors of the respiratory mucosa. Induces bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors. Available in 30- and 60-mg tablets, 30-mg/5 mL elixir, and in a sustained-release form 120 mg. |
| Adult Dose | 60 mg PO q4-6h; 120 mg SR q12h; not to exceed 240 mg/d |
| Pediatric Dose | 3-12 months: 3 gtt/kg q4-6h; not to exceed 4 doses/d 1-2 years: 7 gtt (0.2 mL)/kg q4-6h; not to exceed 4 doses/d 2-5 years: 15 mg PO q4-6h; not to exceed 60 mg/d >5 years: 30 mg PO q4-6h; not to exceed 120 mg/d |
| Contraindications | Documented hypersensitivity; severe anemia; postural hypertension and hypotension; closed-angle glaucoma; head trauma; cerebral hemorrhage |
| Interactions | Propranolol, MAOIs, and sympathomimetic agents may increase toxicity of pseudoephedrine; methyldopa and reserpine may reduce effects of pseudoephedrine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in cardiovascular disease, diabetes mellitus, prostatic hypertrophy, and increased intraocular pressure |
Empiric coverage for H influenzae and S pneumoniae; in addition to M catarrhalis in children.
| Drug Name | Trimethoprim and sulfamethoxazole (Bactrim, Septra) |
|---|---|
| Description | Inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. By inhibiting the enzyme dihydrofolate reductase, the production of tetrahydrofolic acid decreases. These effects inhibit bacterial growth. Bacterial resistance appears to develop more slowly with this drug combination than with either drug alone. DOC along with AMP/CL. Available in elixir 40/200 per 5 mL, single strength (80/400) and double strength (160/800). |
| Adult Dose | 5 mg/kg (based on trimethoprim) IV q6h; 1 tab (double strength) PO bid |
| Pediatric Dose | 5 mL/10 kg/dose elixir PO bid |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue at first appearance of rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholism, elderly persons, those receiving anticonvulsant therapy, or those with malabsorption syndrome); hemolysis may occur in G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation |
| Drug Name | Amoxicillin and clavulanate (Augmentin) |
|---|---|
| Description | Drug combination that extends the antibiotic spectrum of penicillin to include bacteria normally resistant to beta-lactam antibiotics. Administer treatment for a minimum of 10 d. Available in 125-, 250-, and 500-mg tablets and in 125 and 250/5 mL elixir. |
| Adult Dose | 500 mg PO q12h; 250 mg PO q8h |
| Pediatric Dose | 30-40 mg/kg/d PO divided tid |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Give for a minimum of 10 d to eliminate organism and prevent sequelae (endocarditis, and rheumatic fever); following treatment, perform cultures to confirm eradication of streptococci |
| Drug Name | Cefaclor (Ceclor) |
|---|---|
| Description | These agents are indicated for the management of infections caused by susceptible mixed aerobic-anaerobic microorganisms. Proper dosage and route of administration should be determined by the condition of the patient, severity of the infection, and susceptibility of the causative organism. |
| Adult Dose | 250 mg PO tid |
| Pediatric Dose | 20-40 mg/kg/d PO divided tid |
| Contraindications | Documented hypersensitivity |
| Interactions | Alcoholic beverages consumed <72 h after taking cefaclor may produce disulfiramlike reactions; may increase hypoprothrombinemic effects of anticoagulants; coadministration with potent diuretics and aminoglycosides (eg, loop diuretics) may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Reduce dosage by half if CrCl is 10-30 mL/min, and by one fourth if <10 mL/min; bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy |
| Drug Name | Amoxicillin (Amoxil, Polymox) |
|---|---|
| Description | Treats infections caused by susceptible organisms and can be used as prophylaxis in minor procedures. An alternative therapy, but some resistant organisms are beginning to be seen in the US. |
| Adult Dose | 250-500 mg PO q8h; not to exceed 3 g/d |
| Pediatric Dose | 20-50 mg/kg/d PO divided tid |
| Contraindications | Documented hypersensitivity |
| Interactions | Reduces the efficacy of oral contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment |
| Drug Name | Clarithromycin (Biaxin) |
|---|---|
| Description | Reversibly binds to the P site of the 50S ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis by stimulating the dissociation of peptidyl tRNA from ribosomes. |
| Adult Dose | 250-500 mg PO q12h for 7-14 d |
| Pediatric Dose | 15 mg/kg PO divided bid |
| Contraindications | Documented hypersensitivity; coadministration of pimozide |
| Interactions | Toxicity increases with coadministration of fluconazole, astemizole, and pimozide; clarithromycin effects decrease, and GI adverse effects may increase with coadministration of rifabutin or rifampin; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, omeprazole, carbamazepine, ergot alkaloids, triazolam, and HMG CoA-reductase inhibitors; cardiac arrhythmias may occur with coadministration of cisapride; plasma levels of certain benzodiazepines may increase, prolonging CNS depression; arrhythmias and increase in QTc intervals occur with disopyramide; coadministration with omeprazole may increase plasma levels of both agents |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Coadministration with ranitidine or bismuth citrate is not recommended with CrCl <25 mL/min; give half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis; superinfections may occur with prolonged or repeated antibiotic therapies |
| Drug Name | Azithromycin (Zithromax) |
|---|---|
| Description | Advanced-generation macrolide works similarly to clarithromycin but with shorter dosage time. |
| Adult Dose | Day 1: 500 mg PO Days 2-5: 250 mg PO qd |
| Pediatric Dose | <6 months: Not established >6 months: Day 1: 10 mg/kg PO once; not to exceed 500 mg/d Days 2-5: 5 mg/kg PO qd; not to exceed 250 mg/d |
| Contraindications | Documented hypersensitivity; hepatic impairment; do not administer with pimozide |
| Interactions | May increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Site reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in hospitalized, geriatric, or debilitated patients |
| Drug Name | Levofloxacin (Levaquin) |
|---|---|
| Description | The S-enantiomer of ofloxacin, a fluoroquinolone antibiotic with improved activity against gram-positive organisms. Best used only in severe or refractory sinusitis. |
| Adult Dose | 500 mg PO qd for 7-21 d |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; levofloxacin reduces therapeutic effects of phenytoin; probenecid may increase levofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Cefpodoxime (Vantin) |
|---|---|
| Description | Second-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have. Adds activity against P mirabilis, H influenzae, E coli, K pneumoniae, and M catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration. |
| Adult Dose | 100-400 mg PO bid |
| Pediatric Dose | 10 mg/kg/d PO divided bid |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid increases effect; coadministration with furosemide and aminoglycosides increases nephrotoxic effects |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dosage in renal impairment |
| Drug Name | Cefuroxime (Ceftin, Zinacef) |
|---|---|
| Description | Second-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have; adds activity against P mirabilis, H influenzae, E coli, K pneumoniae, and M catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration. |
| Adult Dose | 250-500 mg PO bid |
| Pediatric Dose | 250 mg PO bid for 20 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h after taking cefuroxime; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics such as loop diuretics; coadministration with aminoglycosides increases nephrotoxic potential |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Administer half dose if creatinine clearance is 10-30 mL/min and one-fourth dose if <10 mL/min; fungal and microorganism overgrowth may occur with prolonged therapy |
Article Last Updated: Aug 8, 2007